How US Pharma Manufacturers Are Balancing Domestic Production and Global Sourcing

Few decisions in the pharmaceutical boardroom have become as politically charged, or as financially consequential, as the question of where a medicine is made. For years, the answer was driven by a simple formula: locate each step of production wherever quality could be assured at the lowest total cost. That formula built an efficient, deeply globalized industry. It also built a system that policymakers in Washington now regard as a national security exposure.

The numbers explain the concern. In congressional testimony, the US Food and Drug Administration (FDA) reported that as of August 2019, only 28 percent of the facilities making active pharmaceutical ingredients (APIs) for the US market were located in the United States, with the remainder spread across Europe, India, China and other regions. A White House fact sheet issued in August 2025 went further, stating that only about 10 percent of the APIs for US prescription drugs are manufactured domestically.

Today, US pharma manufacturers face a dual mandate. They are being pushed, through tariffs, procurement signals and regulatory incentives, to build more capacity at home. At the same time, they cannot abandon global networks that deliver specialised chemistry, cost competitiveness and scale. The companies pulling ahead are not choosing one model over the other. They are engineering a deliberate balance.

The New Pharma Supply Equation: Why Location Is Now a Boardroom Decision

The shift began as a resilience conversation and has become a commercial one. Drug shortages, pandemic-era export restrictions and periodic quality failures exposed how a single disrupted site could ripple across the entire US market. The FDA's own analysis found that 163 drugs went into shortage between 2013 and 2017, and that quality problems were behind 62 percent of those shortages.

What has changed in the past two years is that supply location now carries a direct price tag. Manufacturing footprint affects tariff exposure, eligibility for government programs, pricing negotiations and investor sentiment. As a result, network design has moved from the operations function into the strategy agenda of CEOs, CFOs and boards.

Pharmaceutical Tariffs Rewrite the Cost of Imported Medicines

The most powerful lever is trade policy. On April 2, 2026, a presidential proclamation under Section 232 imposed a standard tariff of 100 percent on listed patented pharmaceuticals and their APIs. The measure took effect on July 31, 2026 for a first group of named companies and on September 29, 2026 for all others.

The design of the proclamation reveals what Washington wants from industry. Companies with approved onshoring plans qualify for a reduced 20 percent rate, which is scheduled to rise to 100 percent on April 2, 2030. Firms that pair onshoring plans with Most-Favored-Nation pricing agreements can pay a 0 percent rate until January 20, 2029. Products from the European Union, Japan, South Korea and Switzerland face a 15 percent rate, while UK products face 10 percent.

Equally important is what the tariffs leave out. Generic medicines, biosimilars and their ingredients are currently excluded, as are US-origin products. Certain specialty categories, including cell and gene therapies, antibody-drug conjugates, plasma-derived therapies and medicines whose approved indications are all orphan-designated, can qualify for a 0 percent rate under defined conditions. For executives, this structure turns the tariff regime into a portfolio-by-portfolio calculation rather than a blanket penalty.

From Stockpiles to Fast-Track Reviews: Washington's Pharma Onshoring Toolkit

Tariffs are only one instrument. On August 13, 2025, an executive order directed the federal government to fill the Strategic Active Pharmaceutical Ingredients Reserve. According to the accompanying White House fact sheet, the order calls for a list of about 26 critical drugs to be prioritized and for a six-month supply of their APIs to be placed in the reserve. It also calls for a plan to secure a six-month API supply for the 86 drugs on the 2022 essential medicines list.

On the regulatory side, the FDA launched its PreCheck pilot on February 1, 2026 to give companies earlier technical engagement while they build new US manufacturing sites. The program works in two phases: facility readiness, which includes FDA review of facility information through a facility-specific Drug Master File, and facility-focused meetings before application submission. The agency received more than 80 requests to participate between February 1 and March 1, 2026 and selected seven participants for the pilot.

Together, these measures send a consistent message. Domestic capacity will be rewarded through lower tariff exposure, potential reserve demand and smoother regulatory pathways. Yet none of them guarantees long-term volume or pricing, which is why most leadership teams are investing selectively rather than relocating wholesale.

Why Global Pharma Sourcing Still Matters

Despite the policy momentum, a fully domestic US supply chain is neither realistic nor desirable in the near term. Generic medicines, which account for the large majority of prescriptions dispensed in the country, operate on margins that rarely support the capital cost of new American API plants. The exclusion of generics from the Section 232 tariffs reflects that reality: aggressive penalties would risk worsening the very shortages policymakers want to prevent.

Global networks also hold capabilities that cannot be replicated quickly. Specialised fermentation, complex chiral chemistry, high-potency containment and mature regulatory track records sit in established hubs across Europe and Asia. Building equivalent expertise in the United States takes years, not quarters, and depends on a skilled workforce that is already in short supply.

The strategic risk, therefore, is not global sourcing itself but concentrated global sourcing. A molecule supplied by a single overseas site, with no qualified alternative, is the real vulnerability. 

Diversification across geographies, including trusted partner countries, can deliver much of the resilience benefit of onshoring at a fraction of the cost.

The Hybrid Pharma Manufacturing Model Taking Shape

Across the industry, a recognizable operating model is emerging. Its starting point is segmentation. Leaders classify their portfolios according to three questions: How exposed is the product to tariffs? How critical is it to patients and public health? And how complex is it to manufacture?

Patented, high-value products with significant tariff exposure are the strongest candidates for US production of both drug substance and drug product. Critical medicines with concentrated supply risk tend to receive dual sourcing, often pairing a domestic or near-shore site with a qualified international partner. Lower-risk, cost-sensitive generics typically remain globally sourced, but with stronger visibility into upstream starting materials and contractual safeguards around continuity.

Technology is narrowing the cost gap for the domestic portion of this model. Continuous manufacturing, process analytical technology, automation and digital batch records reduce labor intensity and footprint, allowing new US facilities to operate with smaller teams and greater consistency. Modular and flexible suites also allow a single site to serve multiple products, improving the return on capital that would otherwise be tied to one molecule.

Case Study: Re-Engineering a Pharma Supply Network for Two Worlds

The following anonymized case reflects a pattern seen across mid-sized US pharmaceutical companies and is presented as an illustrative composite rather than the record of a single named organization.

A US-headquartered specialty pharmaceutical company held a portfolio split between a handful of patented brands and a larger base of established generics. Its APIs were sourced almost entirely from overseas contract manufacturers, and several patented products depended on a single foreign supplier.

When the Section 232 framework was announced, the leadership team avoided a reflexive response. Instead, it mapped every product by tariff exposure, clinical criticality and manufacturing complexity. The analysis showed that a small number of patented brands generated most of the potential tariff cost, while the generics portfolio was largely outside the scope of the measures.

The company concentrated its capital on the patented products. It contracted with a US-based manufacturer for final drug product, began technology transfer of one key API to a domestic partner, and prepared an onshoring plan to qualify for the reduced tariff tier while new capacity came online. For its critical generics, it qualified a second international supplier in a different region rather than building domestic capacity it could not justify economically.

The result was a network designed for two realities at once: lower tariff exposure and stronger continuity for the products that mattered most, without sacrificing the cost competitiveness of its generics business. The lesson for leadership teams is that balance comes from precise segmentation, not from blanket relocation.

The Pharma Talent and Capital Equation Behind Domestic Production

Even well-designed onshoring strategies face practical constraints. New pharmaceutical plants require long lead times for design, construction, validation and regulatory approval. Skilled process engineers, quality professionals and technicians are in high demand, and competition for that talent will intensify as more projects break ground.

Capital discipline is equally important. Policy incentives can shift, and the reduced tariff tiers carry defined end dates. Executives are therefore stress-testing investments against multiple scenarios, favoring flexible facilities, phased build-outs and partnerships with contract manufacturers that spread risk while still delivering domestic capacity.

Conclusion

The debate over domestic production versus global sourcing is often framed as a binary choice. For US pharma manufacturers, the reality is more nuanced. Tariffs, strategic reserves and new FDA programs are making American production more attractive for high-value and critical products, while the economics of generics and the depth of global expertise ensure that international partners remain indispensable.

The winners in this environment will be companies that treat supply network design as a core strategic capability. By segmenting portfolios carefully, investing where policy and economics align, and diversifying rather than simply relocating, pharma leaders can protect margins, satisfy policymakers and, above all, keep medicines reaching American patients without interruption.

Frequently Asked Questions

1.    Why are US pharma manufacturers increasing domestic production now?

Section 232 tariffs on patented pharmaceuticals, federal efforts to build a strategic API reserve, FDA support for new US facilities and growing concern about supply concentration have all raised the value of domestic capacity.

2.    Do the Section 232 pharmaceutical tariffs apply to generic medicines?

No. Under the April 2026 proclamation, generic medicines, biosimilars and their ingredients are currently excluded, as are US-origin products.

3.    What is the Strategic Active Pharmaceutical Ingredients Reserve?

It is a federal reserve of APIs. An executive order signed on August 13, 2025 directs a six-month supply of APIs for about 26 prioritized critical drugs to be placed in it.

4.    What is the FDA PreCheck program?

Launched as a pilot on February 1, 2026, PreCheck offers earlier FDA technical engagement to companies building new US manufacturing facilities. It does not pre-approve sites or products.

5.    Will US pharma companies stop sourcing globally?

Unlikely. Most are adopting hybrid models that onshore high-value, tariff-exposed or critical products while diversifying global suppliers for cost-sensitive generics.